Chest
ORIGINAL RESEARCHPULMONARY VASCULAR DISEASELarge and Medium-Sized Pulmonary Artery Obstruction Does Not Play a Role of Primary Importance in the Etiology of Sickle-Cell Disease-Associated Pulmonary Hypertension
Section snippets
Patients
Consecutive SCD patients visiting the outpatient hematology/internal medicine clinics of the Academic Medical Center (Amsterdam, the Netherlands), the Slotervaart Hospital (Amsterdam, the Netherlands), and the Erasmus Medical Center (Rotterdam, the Netherlands) were eligible for this study. Inclusion criteria were high-performance liquid chromatography-confirmed diagnosis of SCD, age ≥ 18 years, and written informed consent. Exclusion criteria were known congestive heart failure, known COPD,
Patients
Ninety consecutive patients were eligible for the study, 5 of whom declined participation. Eighty-five patients were included in the study. For data analysis, the more severe SCD genotypes, HbSS and HbSβ0-thalassemia, were grouped together, as were the relatively milder SCD genotypes HbSβ+-thalassemia and HbSC.1920 For patient demographics, see Table 1.
Transthoracic Echocardiography
Transthoracic echocardiography was performed in 78 of the 85 included patients because 7 patients failed to meet their appointment on several
Discussion
A landmark study1 demonstrated that PHT occurs in approximately 30% of adult SCD patients and carries a strongly increased risk of death as compared to SCD patients without PHT. Given this risk of early death, it is of paramount importance to identify treatable causes and/or aggravating factors of PHT in SCD. In this study, we investigated the potential role of pulmonary artery obstruction as a causative or contributing factor in SCD patients with PHT employing VQ scintigraphy. VQ scintigraphy
ACKNOWLEDGMENT
Dr. C. Hoefnagel, Dr. A. de Groot, Dr. C. Schotborgh, Dr. K.W. Lagrand, and Ms. A. Karisli are gratefully acknowledged for contributing to the study design and execution.
References (27)
- et al.
Pulmonary hypertension in sickle cell disease
Am J Med
(2004) - et al.
The hypercoagulable state in thalassemia
Blood
(2002) - et al.
Thrombotic arteriopathy and anticoagulation in pulmonary hypertension
Chest
(2006) - et al.
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Sickle cell acute chest syndrome: pathogenesis and rationale for treatment
Blood
(1999) - et al.
Perfusion lung scans vs pulmonary angiography in evaluation of suspected primary pulmonary hypertension
Chest
(1983) - et al.
Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound
J Am Coll Cardiol
(1985) - et al.
Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure
J Am Coll Cardiol
(1987) - et al.
Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management
Hematol Oncol Clin North Am
(2005) - et al.
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease
N Engl J Med
(2004)
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study
Br J Haematol
β-Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability
Br J Haematol
Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension
Br J Haematol
Cited by (0)
The authors have no conflicts of interest to disclose.
- †
The CURAMA study group is a collaborative effort studying SCD in the Netherlands Antilles and the Netherlands. Participating centers include The Red Cross Blood Bank Foundation, Curaçao, the Netherlands Antilles; The Antillean Institute for Health Research, Curaçao, the Netherlands Antilles; The Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands; the Department of Vascular Medicine and the Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands; the Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands; the Department of Pathology, Groningen University Hospital, Groningen, the Netherlands; the Department of Internal Medicine, the Laboratory of Clinical Thrombosis and Hemostasis, and the Cardiovascular Research Institute, Academic Hospital Maastricht, Maastricht, the Netherlands